CD274 and neoplasm: The global, multicenter, open-label phase Ia/Ib dose-escalation and dose-expansion study (GO30103; NCT02794571) investigated the safety, pharmacokinetic (PK), and preliminary anti-tumor activity of tiragolumab as a single agent and in combination with the PD-L1-inhibitor atezolizumab in patients with advanced/metastatic solid tumors [13].